NCT01863589已完成不适用
Drug Use Investigation for HEPSERA (Adefovir) Tablet
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 436
- 主要终点
- The incidence of adverse drug reactions
研究概览
简要总结
This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir tablets.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with chronic hepatitis B or hepatic cirrhosis B
- •Subjects treated with adefovir tablets
排除标准
- 未提供
研究组 & 干预措施
Subjects prescribed adefovir tablets
Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
干预措施: Adefovir tablets (Drug)
结局指标
主要结局
The incidence of adverse drug reactions
时间窗: 1 year
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term UseHypertensionNCT01050062Boehringer Ingelheim1,452
已完成
不适用
Drug Use Investigation for Arepanrix® (H1N1)InfluenzaNCT02069496GlaxoSmithKline3,405
撤回
不适用
A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino PatientsHuman Immunodeficiency Virus-Type 1NCT01726348Janssen Pharmaceutica
已完成
不适用
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism TreatmentAtaxiaNCT01428531GlaxoSmithKline200
已完成
不适用
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) InjectionThromboembolismNCT01420809GlaxoSmithKline1,280